MX368178B - Compuestos de ácido dimetilbenzoico. - Google Patents
Compuestos de ácido dimetilbenzoico.Info
- Publication number
- MX368178B MX368178B MX2016007861A MX2016007861A MX368178B MX 368178 B MX368178 B MX 368178B MX 2016007861 A MX2016007861 A MX 2016007861A MX 2016007861 A MX2016007861 A MX 2016007861A MX 368178 B MX368178 B MX 368178B
- Authority
- MX
- Mexico
- Prior art keywords
- acid compounds
- dimethylbenzoic acid
- dimethylbenzoic
- receptor
- inhibitor
- Prior art date
Links
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical class CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 title 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
(ver Fórmula) La presente invención proporciona un compuesto de la fórmula I: en donde A es: y W, Y, X, R1, R2, R3 y R4 son como se definen en la presente, o una sal de éste aceptable desde el punto de vista farmacéutico, para uso como un inhibidor del receptor de EP4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916824P | 2013-12-17 | 2013-12-17 | |
| PCT/US2014/069783 WO2015094912A1 (en) | 2013-12-17 | 2014-12-11 | Dimethylbenzoic acid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007861A MX2016007861A (es) | 2017-01-11 |
| MX368178B true MX368178B (es) | 2019-09-23 |
Family
ID=52355186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007861A MX368178B (es) | 2013-12-17 | 2014-12-11 | Compuestos de ácido dimetilbenzoico. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10005721B2 (es) |
| EP (1) | EP3083554B1 (es) |
| JP (1) | JP6200596B2 (es) |
| KR (1) | KR101937186B1 (es) |
| CN (1) | CN105793236B (es) |
| AU (1) | AU2014366371B2 (es) |
| CA (1) | CA2929562A1 (es) |
| CY (1) | CY1121677T1 (es) |
| DK (1) | DK3083554T3 (es) |
| EA (1) | EA028675B1 (es) |
| ES (1) | ES2727329T3 (es) |
| HR (1) | HRP20190793T1 (es) |
| HU (1) | HUE043614T2 (es) |
| LT (1) | LT3083554T (es) |
| ME (1) | ME03398B (es) |
| MX (1) | MX368178B (es) |
| PL (1) | PL3083554T3 (es) |
| PT (1) | PT3083554T (es) |
| RS (1) | RS58594B1 (es) |
| SA (1) | SA516371324B1 (es) |
| SI (1) | SI3083554T1 (es) |
| TR (1) | TR201904327T4 (es) |
| WO (1) | WO2015094912A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107074773A (zh) * | 2014-09-09 | 2017-08-18 | 拜耳制药股份公司 | 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途 |
| US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2017153235A1 (de) * | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
| AU2018251758B2 (en) | 2017-04-10 | 2021-11-18 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| US20200069686A1 (en) | 2017-05-18 | 2020-03-05 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| AR111941A1 (es) | 2017-05-18 | 2019-09-04 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| MX388257B (es) | 2017-05-18 | 2025-03-19 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Pge2レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| KR102861190B1 (ko) * | 2019-01-22 | 2025-09-17 | 키테라 (쑤저우) 바이오-파마슈티컬스 컴퍼니 리미티드 | Pge2/ep4 신호 전달을 억제하기 위한 화합물, 이의 제조 방법, 및 이의 의약적 용도 |
| EP4245301A4 (en) | 2020-11-13 | 2024-08-21 | ONO Pharmaceutical Co., Ltd. | TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270615B (it) * | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
| TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
| JP2002539187A (ja) * | 1999-03-17 | 2002-11-19 | アストラゼネカ アクチボラグ | アミド誘導体 |
| RS20060143A (sr) * | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2 |
| PL1664016T3 (pl) | 2003-09-22 | 2009-04-30 | Euro Celtique Sa | Środki terapeutyczne przydatne do leczenia bólu |
| GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US7326732B2 (en) | 2004-02-12 | 2008-02-05 | Pharmagene Laboratories Limited | EP2 receptor agonists |
| CN1950334A (zh) * | 2004-05-04 | 2007-04-18 | 辉瑞有限公司 | 邻位取代的芳基或杂芳基酰胺化合物 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| US20110028463A1 (en) * | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| WO2010043592A1 (en) | 2008-10-15 | 2010-04-22 | Revotar Biopharmaceuticals Ag | Lipase inhibitors for use for the treatment of obesity |
| SG173027A1 (en) * | 2009-01-30 | 2011-08-29 | Toyama Chemical Co Ltd | N-acyl anthranilic acid derivative or salt thereof |
| AU2010231058A1 (en) * | 2009-03-31 | 2011-11-10 | Renascience Co., Ltd. | Plasminogen activator inhibitor-1 inhibitor |
| WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
| US20140057953A1 (en) | 2011-03-03 | 2014-02-27 | Rolf Hartmann | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
| BR112014004545A2 (pt) * | 2011-08-31 | 2017-04-04 | Amakem Nv | inibidores leves de rock |
| WO2013037705A2 (en) * | 2011-09-16 | 2013-03-21 | Fovea Pharmaceuticals | Aniline derivatives,their preparation and their therapeutic application |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
| EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
-
2014
- 2014-12-11 DK DK14827908.6T patent/DK3083554T3/da active
- 2014-12-11 PL PL14827908T patent/PL3083554T3/pl unknown
- 2014-12-11 US US15/030,891 patent/US10005721B2/en not_active Expired - Fee Related
- 2014-12-11 ME MEP-2019-106A patent/ME03398B/me unknown
- 2014-12-11 HU HUE14827908A patent/HUE043614T2/hu unknown
- 2014-12-11 RS RS20190469A patent/RS58594B1/sr unknown
- 2014-12-11 JP JP2016538636A patent/JP6200596B2/ja not_active Expired - Fee Related
- 2014-12-11 EA EA201690911A patent/EA028675B1/ru not_active IP Right Cessation
- 2014-12-11 PT PT14827908T patent/PT3083554T/pt unknown
- 2014-12-11 SI SI201431139T patent/SI3083554T1/sl unknown
- 2014-12-11 WO PCT/US2014/069783 patent/WO2015094912A1/en not_active Ceased
- 2014-12-11 TR TR2019/04327T patent/TR201904327T4/tr unknown
- 2014-12-11 AU AU2014366371A patent/AU2014366371B2/en not_active Ceased
- 2014-12-11 KR KR1020167015772A patent/KR101937186B1/ko not_active Expired - Fee Related
- 2014-12-11 ES ES14827908T patent/ES2727329T3/es active Active
- 2014-12-11 EP EP14827908.6A patent/EP3083554B1/en active Active
- 2014-12-11 MX MX2016007861A patent/MX368178B/es active IP Right Grant
- 2014-12-11 HR HRP20190793TT patent/HRP20190793T1/hr unknown
- 2014-12-11 CN CN201480066576.6A patent/CN105793236B/zh not_active Expired - Fee Related
- 2014-12-11 LT LTEP14827908.6T patent/LT3083554T/lt unknown
- 2014-12-11 CA CA2929562A patent/CA2929562A1/en not_active Abandoned
-
2016
- 2016-06-14 SA SA516371324A patent/SA516371324B1/ar unknown
-
2019
- 2019-05-08 CY CY20191100495T patent/CY1121677T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10005721B2 (en) | 2018-06-26 |
| AU2014366371A1 (en) | 2016-05-19 |
| PT3083554T (pt) | 2019-06-11 |
| KR20160086905A (ko) | 2016-07-20 |
| HUE043614T2 (hu) | 2019-08-28 |
| AU2014366371B2 (en) | 2017-02-16 |
| CN105793236A (zh) | 2016-07-20 |
| KR101937186B1 (ko) | 2019-01-10 |
| SA516371324B1 (ar) | 2018-03-22 |
| PL3083554T3 (pl) | 2019-08-30 |
| LT3083554T (lt) | 2019-05-10 |
| SI3083554T1 (sl) | 2019-04-30 |
| US20160251306A1 (en) | 2016-09-01 |
| ME03398B (me) | 2020-01-20 |
| MX2016007861A (es) | 2017-01-11 |
| JP6200596B2 (ja) | 2017-09-20 |
| WO2015094912A1 (en) | 2015-06-25 |
| CY1121677T1 (el) | 2020-07-31 |
| HRP20190793T1 (hr) | 2019-06-28 |
| EA201690911A1 (ru) | 2016-09-30 |
| CN105793236B (zh) | 2017-10-10 |
| TR201904327T4 (tr) | 2019-04-22 |
| EA028675B1 (ru) | 2017-12-29 |
| EP3083554B1 (en) | 2019-03-13 |
| RS58594B1 (sr) | 2019-05-31 |
| CA2929562A1 (en) | 2015-06-25 |
| ES2727329T3 (es) | 2019-10-15 |
| DK3083554T3 (da) | 2019-05-13 |
| JP2017500309A (ja) | 2017-01-05 |
| EP3083554A1 (en) | 2016-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX368178B (es) | Compuestos de ácido dimetilbenzoico. | |
| JO3317B1 (ar) | مركبات تترا هيدروبيرولو ثيازين | |
| PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PH12014500883A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| NZ725165A (en) | Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors | |
| JO3318B1 (ar) | مثبطات bace | |
| NZ715776A (en) | Polymorph of syk inhibitors | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| UA114325C2 (uk) | Феноксіетилпіперидинові сполуки | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| PH12014502492A1 (en) | Pyrazole compounds as sglt1 inhibitors | |
| PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
| EA201690593A1 (ru) | Новые соединения мочевины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |